Salt-inducible kinase 2 confers radioresistance in colorectal cancer by facilitating homologous recombination repair

Abstract

Resistance to radiotherapy remains a critical barrier in treating colorectal cancer (CRC), particularly in cases of locally advanced rectal cancer (LARC). To identify key kinases involved in CRC radioresistance, we employed a kinase-targeted CRISPR-Cas9 library screen. This approach aimed to identify potential kinase inhibitors as radiosensitizers. Our screening identified salt-inducible kinase 2 (SIK2) as a critical factor in CRC radioresistance. Increased SIK2 expression correlated with reduced tumor regression and poorer outcomes in LARC patients undergoing neoadjuvant chemoradiotherapy. The depletion of SIK2 significantly enhanced radiation-induced apoptosis and tumor regression. Mechanistically, SIK2 interacts with valosin-containing protein (VCP), promoting its hyperphosphorylation. This modification improves VCP’s capacity to extract K48-linked ubiquitin-conjugated proteins from chromatin, thus aiding the recruitment of RPA and RAD51 to DNA damage sites. This mechanism strengthens homologous recombination–mediated DNA repair, which contributes to radioresistance. Importantly, ARN-3236, a SIK2 inhibitor, markedly sensitized CRC cells to radiation both in vivo and in vitro, providing a potential strategy to overcome radioresistance. In summary, our findings reveal a novel mechanism by which SIK2 contributes to the radioresistance of CRC, proposing SIK2 as a potential therapeutic target with its inhibitor significantly enhancing CRC radiotherapy efficacy.

Keywords

colorectal cancer / CRISPR-Cas9 screen / homologous recombination / SIK2

References

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49.

[2] Body A, Prenen H, Lam M, et al. Neoadjuvant therapy for locally advanced rectal cancer: recent advances and ongoing challenges. Clin Colorectal Cancer. 2021; 20(1): 29-41.

[3] Foersch S, Glasner C, Woerl AC, et al. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat Med. 2023; 29(2): 430-439.

[4] Slipsager A, Henrichsen SN, Falkmer UG, Dybkaer K, Belting M, Poulsen LO. Predictive biomarkers in radioresistant rectal cancer: a systematic review. Crit Rev Oncol Hematol. 2023; 186: 103991.

[5] Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020; 5(1): 60.

[6] Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016; 16(1): 20-33.

[7] Tan J, Sun X, Zhao H, Guan H, Gao S, Zhou PK. Double-strand DNA break repair: molecular mechanisms and therapeutic targets. MedComm. 2023; 4(5): e388.

[8] Lee JH, Paull TT. Cellular functions of the protein kinase ATM and their relevance to human disease. Nat Rev Mol Cell Biol. 2021; 22(12): 796-814.

[9] Gelot C, Kovacs MT, Miron S, et al. Poltheta is phosphorylated by PLK1 to repair double-strand breaks in mitosis. Nature. 2023; 621(7978): 415-422.

[10] Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015; 36(7): 422-439.

[11] Henriksson E, Jones HA, Patel K, et al. The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes. Biochem J. 2012; 444(3): 503-514.

[12] Lu Z, Mao W, Yang H, et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest. 2022; 132(11): e146471.

[13] Zhou J, Alfraidi A, Zhang S, et al. A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin Cancer Res. 2017; 23(8): 1945-1954.

[14] Lombardi MS, Gillieron C, Dietrich D, Gabay C. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. J Leukoc Biol. 2016; 99(5): 711-721.

[15] Jiang Y, Huang S, Zhang L, et al. Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer. MedComm. 2024; 5(4): e537.

[16] Smallwood HS, Lopez-Ferrer D, Eberlein PE, Watson DJ, Squier TC. Calmodulin mediates DNA repair pathways involving H2AX in response to low-dose radiation exposure of RAW 264.7 macrophages. Chem Res Toxicol. 2009; 22(3): 460-470.

[17] Katoh Y, Takemori H, Lin XZ, et al. Silencing the constitutive active transcription factor CREB by the LKB1-SIK signaling cascade. FEBS J. 2006; 273(12): 2730-2748.

[18] Zhou J, Nie RC, He ZP, et al. STAG2 regulates homologous recombination repair and sensitivity to ATM inhibition. Adv Sci (Weinh). 2023; 10(36): e2302494.

[19] Meerang M, Ritz D, Paliwal S, et al. The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks. Nat Cell Biol. 2011; 13(11): 1376-1382.

[20] Ramadan K. p97/VCP-and Lys48-linked polyubiquitination form a new signaling pathway in DNA damage response. Cell Cycle. 2012; 11(6): 1062-1069.

[21] Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T. Phosphate-binding tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics. 2006; 5(4): 749-757.

[22] van den Boom J, Wolf M, Weimann L, et al. VCP/p97 extracts sterically trapped Ku70/80 rings from DNA in double-strand break repair. Mol Cell. 2016; 64(1): 189-198.

[23] Acs K, Luijsterburg MS, Ackermann L, Salomons FA, Hoppe T, Dantuma NP. The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol. 2011; 18(12): 1345-1350.

[24] Yang FC, Lin YH, Chen WH, et al. Interaction between salt-inducible kinase 2 (SIK2) and p97/valosin-containing protein (VCP) regulates endoplasmic reticulum (ER)-associated protein degradation in mammalian cells. J Biol Chem. 2013; 288(47): 33861-33872.

[25] Zhu C, Rogers A, Asleh K, et al. Phospho-Ser(784)-VCP is required for DNA damage response and is associated with poor prognosis of chemotherapy-treated breast cancer. Cell Rep. 2020; 31(10): 107745.

[26] Yue X, Liu T, Wang X, et al. Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1-BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy. Acta Pharm Sin B. 2023; 13(8): 3382-3399.

[27] Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin. 2004; 25(2): 146-147.

[28] Ferrandon S, DeVecchio J, Duraes L, et al. CoA synthase (COASY) mediates radiation resistance via PI3K signaling in rectal cancer. Cancer Res. 2020; 80(2): 334-346.

[29] Chen F, Chen L, Qin Q, Sun X. Salt-inducible kinase 2: an oncogenic signal transmitter and potential target for cancer therapy. Front Oncol. 2019; 9: 18.

[30] Sun Z, Jiang Q, Li J, Guo J. The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Signal Transduct Target Ther. 2020; 5(1): 150.

[31] Bon H, Wadhwa K, Schreiner A, et al. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Mol Cancer Res. 2015; 13(4): 620-635.

[32] Nagel S, Leich E, Quentmeier H, et al. Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma. Leuk Lymphoma. 2010; 51(5): 881-891.

[33] Ni X, Feng Y, Fu X. Role of salt-inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells. Mol Med Rep. 2021; 24(5).

[34] Shi X, Yu X, Wang J, et al. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Mol Oncol. 2022; 16(13): 2558-2574.

[35] Gao T, Zhang X, Zhao J, et al. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1alpha pathway and Drp1-mediated mitochondrial fission in ovarian cancer. Cancer Lett. 2020; 469: 89-101.

[36] Miranda F, Mannion D, Liu S, et al. Salt-inducible kinase 2 couples ovarian cancer cell metabolism with survival at the adipocyte-rich metastatic niche. Cancer Cell. 2016; 30(2): 273-289.

[37] Rong Z, Zhang L, Li Z, et al. SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling. Oncogene. 2022; 41(16): 2390-2403.

[38] Ahmed AA, Lu Z, Jennings NB, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010; 18(2): 109-121.

[39] Clark K, MacKenzie KF, Petkevicius K, et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012; 109(42): 16986-16991.

[40] Chan KK, Abdul-Sater Z, Sheth A, et al. SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells. Mol Oncol. 2022; 16(4): 860-884.

[41] Jiang N, Shen Y, Fei X, et al. Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells. Cell Death Dis. 2013; 4(5): e647.

[42] Kieffer SR, Lowndes NF. Immediate-early, early, and late responses to DNA double stranded breaks. Front Genet. 2022; 13: 793884.

[43] Wang XC, Yue X, Zhang RX, et al. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating nonhomologous end joining repair. Clin Cancer Res. 2019; 25(14): 4567-4579.

[44] Peng QH, Wang CH, Chen HM, et al. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer. 2021; 9(2): e001638.

[45] Kuang CM, Fu X, Hua YJ, et al. BST2 confers cisplatin resistance via NF-kappaB signaling in nasopharyngeal cancer. Cell Death Dis. 2017; 8(6): e2874.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.